Modèles de partenariats Public-Privé en France et en Europe

Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products www.fda.gov/oc/initiatives/criticalpath/whitepaper.html Zerhouni, 2003, The NIH Roadmap, Science, 302, 63, 10.1126/science.1091867 Zerhouni, 2005, Translational and clinical science – time for a new vision, NEJM, 353, 1621, 10.1056/NEJMsb053723 Fischer, 2005, The Europen rare disease thertapeutic initiative. A PPP is promoting research on new treatments for rare diseases, PLoS Medicine, 2, e243, 10.1371/journal.pmed.0020243 Frantz, 2005, PPPs succeeding in tackling neglected diseases, Nature Rev Drug Discov, 4, 796 Rawlins, 2004, Cutting the cost of drug development ?, Nature Rev Drug Discov, 3, 360, 10.1038/nrd1347 Ray, 2006, Reform of drug regulation - beyond an independent drug safety board, NEJM, 354, 194, 10.1056/NEJMsb053432 http://www.medichildren.net/ Donnelly, 2005, European Technology Platform on Innovative Medicines, Int J Pharm Med, 19, 153, 10.2165/00124363-200519030-00003 SRA on Stossel, 2005, Regulating acaademic-industrial research relationships - solving problems or stifling progress ?, NEJM, 353, 1060, 10.1056/NEJMsb051758 Kola, 2004, Can the pharmaceurical industry reduce attrition rates ?, Nature Rev Drug Discov, 3, 711, 10.1038/nrd1470 Nissim, 2004, Methods for targeting biologicals to specific disease sites, Trends Mol Med, 10, 269, 10.1016/j.molmed.2004.04.003 Fishman, 2005, A new grammar for drug discovery, Nature, 437, 491, 10.1038/437491a Singer, 2005, Personalized medicine prompts push to redisgn clinical trials.Editorial, Nature Med, 11, 462, 10.1038/nm0505-462a The Royal Society, 2005, 1 Couvreur, 2005, EUFEPS report : contribution of academic research to discovery and development of medicines : current status and future opportunities, Eur J Pharm Sci, 24, 245, 10.1016/j.ejps.2004.12.001 Marionnet, 2004, PME, innovations technologiques et secteurs d’application.Pharma-Biotech. OSEO-ANVAR, Direction Technologie Projets Européens, 1 Demotes-Mainard, 2005, European Clinical Research Infrastructures Network : promoting harmonisation and quality in European clinical research, Lancet, 365, 107, 10.1016/S0140-6736(05)17720-4 Demotes-Mainard, 2005, How to exploit existing assets and resources in Europe ?, 21 LEEM/AD Little, 2005, Optimisation de l’attractivité de la France pour la production biologique Demotes-Mainard, 2005, Clinical research infrastructures and networks in France : report on the french ECRIN workshop, Thérapie, 60, 183, 10.2515/therapie:2005023 Clément, 2005, Le réseau des Centres de Ressources Biologiques Humains. Une infrastructure essentielle pour la recherche biomédicale en Europe, Thérapie, 60, 351, 10.2515/therapie:2005049 Fitzgerald, 2005, Anticipating change in drug development: the emerging era of translational medicine and therapeutics, Nature Rev Drug Discov, 4, 815, 10.1038/nrd1849 Vlahakes, 2006, The value of phase 4 clinical testing, NEJM, 354, 413, 10.1056/NEJMe058272 Remuzzi, 2004, Independent clinical research in Europe, Lancet, 364, 17232, 10.1016/S0140-6736(04)17360-1